• Intuitive Surgical (NasdaqGS: ISRG) faces new U.S. competition after Johnson & Johnson received FDA authorization for its Ottava robotic surgical system.
• Ottava is positioned as a space saving robotic platform that could widen the market for hospitals and surgical centers considering robotic surgery.
• Johnson & Johnson plans to pair Ottava with its existing surgical tools and devices, creating a fresh challenge to Intuitive Surgical's installed base and recurring revenue streams.

Consider broadening your watchlist to other companies involved in surgical robotics and automation through 39 robotics and automation stocks.

Intuitive Surgical is a US based medical equipment company that develops robotic systems and tools to support minimally invasive procedures for hospitals and healthcare providers worldwide. With a market cap of $141.7b, it is a large player in surgical robotics as Johnson & Johnson brings Ottava to market.

How serious a competitive threat is Johnson & Johnson’s Ottava to Intuitive Surgical in the U.S.?

Ottava gives Johnson & Johnson a foothold in U.S. soft tissue robotic surgery and directly targets the operating rooms where Intuitive Surgical’s da Vinci systems are used today. Its table integrated, space saving design may appeal to hospitals that currently cannot accommodate larger robotic setups. This could make new tenders and replacement cycles more contested.

Does Ottava change the existing Intuitive Surgical Narrative?

The Narrative leans on strong procedure growth, a growing installed base and high recurring revenue from instruments and services. Ottava challenges the Narrative risk that increased competition and remanufactured or extended use instruments could pressure Intuitive Surgical’s recurring revenue, especially if hospitals use J&J’s broader surgical portfolio to negotiate pricing or shift volumes.

If we take a look at the community Narrative for Intuitive Surgical, we can see how this news fits into the bigger investment story.

What needs to happen next for Ottava to really move the needle for Intuitive Surgical investors?

The key datapoints are future disclosure on Ottava system placements, procedure volumes and any impact on Intuitive Surgical’s reported U.S. procedure growth and installed base metrics. Quarterly updates over the next few earnings cycles will show whether Ottava mainly expands the total robotic market or starts to displace da Vinci systems in core specialties.

For the full picture including more risks and rewards, check out the complete Intuitive Surgical analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.